Trimetazidine in Pulmonary Artery Hypertension

Inclusion Criteria

• •PAH patients belonging to the following subgroups of the updated Dana Point Classification Group 1
• •1. Idiopathic PAH
• •2. Heritable PAH
• •3. Drug or toxin-induced PAH
• •4. PAH associated with connective tissue disease
• •5. PAH associated to congenital heart disease with simple systemic-to-pulmonary shunt at least 1 year after surgical repair
• •6. PAH associated to HIV infection
• •Documented hemodynamic diagnosis of PAH by right ventricular catheterization performed any time prior to screening
• •Signed informed consent
• •Patients belonging to the groups 2-5 of the updated Dana Point Classification Group
• •Moderate to severe chronic pulmonary obstructive disease
• •Documented left ventricular dysfunction
• •Severe renal impairment (Serum creatinine \> 2.5 mg/dL)
• •Patients who are receiving or have been receiving any investigational drugs within 1 month before the baseline visit
• •Acute or chronic impairment (other than dyspnea) limiting the ability to comply with study requirements
• •Psychotic, addictive or other disorder limiting the ability to provide informed consent or to comply with study requirements
• •Life expectancy less than 12 months
• •Females who are lactating or pregnant or those who plan to become pregnant during the study
• •Known hypersensitivity to any of the excipients of the drug formulation